Vertex clinches Trikafta and other cystic fibrosis drug reimbursement deal in England

Fierce Pharma June 21, 2024
Fraiser Kansteiner

Cystic fibrosis (CF) patients and their families in England can rest a little easier this week, thanks to an extended long-term reimbursement deal inked by Vertex Pharmaceuticals and the country’s National Health Service (NHS).

The accord comes after years of back-and-forth in the United Kingdom over the cost of Vertex’s life-saving—yet expensive—CF drugs.

Vertex announced the updated reimbursement deal with the NHS on Thursday, which ensures access to the drugmaker’s CF meds Trikafta (known as Kaftrio in the U.K.), Symkevi and Orkambi for all existing and future eligible cystic fibrosis patients in England.

It’s expected that similar deals will soon materialize in Wales, Scotland and Northern Ireland, according to the British Broadcasting Corporation (BBC).

The agreement comes after the U.K.’s...

Today's Sponsors

Today's Sponsor